



ISV Member Newsletter

July 2025

Download PDF

## FROM THE PRESIDENTS DESK



**LINDA KLAVINSKIS**  
PhD, ISV President

International  
Society for  
VACCINES

**Dear Members of the International Society for Vaccines,**

The past month has been a busy and exciting time at ISV. I'd like to take a moment to share key updates, recognize our collective achievements, and highlight meaningful opportunities for you to engage with the Society and the global vaccine community.

### **2025 Annual Congress – Stellenbosch, South Africa (October 28–30)**

Preparations for our 2025 Annual Congress are nearing completion, and I'm delighted to announce that abstract submissions have exceeded expectations. This enthusiastic response reflects the vitality, resilience, and innovation of our global vaccine community, especially considering ongoing funding challenges affecting academia and biotech/pharma alike.

Over the past few weeks, a large panel of experts has been evaluating Abstract submissions. This vital work enables our Congress Co-Chairs to develop a high-quality scientific program that captures the breadth and depth of innovation across the field of vaccinology. I would like to extend my sincere thanks to all those who participated in this process; your time, expertise, and thoughtful evaluations are deeply appreciated. Our Program Co-Chairs are now finalizing a dynamic agenda that will showcase cutting-edge research spanning the entire vaccine development pipeline. We're especially committed to providing early-career researchers with opportunities to present their work and receive valuable feedback.

A stellar lineup of invited speakers from around the world has also been confirmed, see [our speakers list](#) thanks to the generous support of the International Vaccine Institute (IVI) through an educational grant.

## Important Dates to Remember

- **Early bird registration closes August 15th** – Take advantage of discounted rates and plan to join us in person!
- **Late-breaker abstract submissions close September 1st** – There's still time to share your latest research.
- **Virtual participation** – If you're unable to travel, consider submitting a poster and joining us online to connect with colleagues and stay engaged.

We look forward to welcoming you to Stellenbosch for what promises to be an inspiring and impactful Congress.

## Congress Travel Awards – Supporting the Next Generation

We're delighted to report record success in securing grant funding to support Trainee participation. To date, **47 fully funded travel awards** have been granted to PhD students and postdocs from LMICs, thanks to the generous support of the **Gates Foundation**, **CEPI**, and the **International Veterinary Vaccinology Network (IVVN)**. Additional awards will soon be announced through funding from the **Poliovirus Research Foundation (PRF)** of South Africa. We're also deeply grateful to ISV members for **personal donations**, which have enabled us to fund **13 additional awards** for Trainees from non-LMIC countries. Your generosity is helping us ensure a more inclusive and representative Congress.

## Mentorship Matters – Get Involved!

While we're on the topic of supporting the next generation, I encourage all members to consider becoming mentors. Your guidance can have a lasting impact on students and early-career professionals in our field. If you're interested in contributing, please email Ted Gibson, ISV Director of Operations at [EdwardGibson@isvcongress.org](mailto:EdwardGibson@isvcongress.org).

## Committee Participation – Your Involvement Matters

Our committees continue to thrive thanks to the energy and commitment of our members. I'm pleased to warmly welcome several new members:

- **Awards & Prizes:** Ebony Gary (Wistar Institute), Jean Boyer (Agenta Therapeutics)
- **Finance and Governance:** Margaret Liu (ProTherImmune; Karolinska Institutet)
- **Global Collaboration and Partnerships:** Davinder Gill (StiRx Inc.), Jeffrey Safrit (Next Frontier Advisors), Kopek Nihlmark (Karolinska Institutet), Alexander Bukreyev (UTMB)
- **Outreach (Paper of the Month Subcommittee):** Celine Lemoine (Vaccine Formulation Institute)
- **Vaccine-Industry and Fundraising:** Xuefei Zhou (XZ GMP Consulting), Corey Fang (AstraZeneca), Ravi Degun (EY-Parthenon)

Whether you're early in your career or a seasoned professional, I warmly invite you to get involved. Committee work is a rewarding way to shape ISV's programs, foster cross-disciplinary connections, and support the development of future vaccinologists. It also offers early-career members an excellent opportunity to enhance visibility and build global networks.

**Lars Frelin**, Chair of the Outreach and Public Engagement Committee ([lars.frelin@ki.se](mailto:lars.frelin@ki.se)) is particularly eager to recruit new members from underrepresented regions, including Asia, Africa, and South America. If you're interested in joining his

committee, please reach out to him directly. For all other committees, feel free to contact me at [President@isv-online.org](mailto:President@isv-online.org)

## Looking Ahead – Governance and Strategic Planning

Nominations for the 2026–2027 ISV Board are about to close. Our Nominations Committee: Dr. Jerome Kim (IVI), Dr. Peter Lawæson Andersen (Novo Nordisk), Dr. Barbara Felber (NCI), along with Dr. Manon Cox (President-elect) and myself will soon begin the review process to prepare the final ballot for member voting in late September.

Additionally, later in the year, we will launch our annual strategic planning process. Broad member input will be sought, and I strongly encourage your participation. Your perspectives are vital to keeping ISV innovative, inclusive, and aligned with the needs of our diverse, global community.

Thank you for your continued engagement and support. ISV is stronger because of your dedication, insight, and shared commitment to advancing vaccine science for the benefit of all.

**Linda Klavinskis, PhD**

President, International Society for Vaccines

## 2025 ISV ANNUAL CONGRESS

**Early Bird Deadline: 15 August 2025**

**Late Breaker Abstract Deadline: 1 September 2025**



**2025 INTERNATIONAL  
SOCIETY FOR VACCINES  
ANNUAL CONGRESS**

**28-30 October 2025**

**Protea Hotel \* Stellenbosch \* South Africa**

**International  
Society for  
VACCINES**



<https://isv-online.org>



[Register Here](#)



# Late BREAKERS

[www.isvcongress2025.co.za](http://www.isvcongress2025.co.za)

**Abstract Submission Deadline: September 1st**

**2025 ISV ANNUAL CONGRESS**

STELLENBOSCH | SOUTH AFRICA | OCTOBER 28-30, 2025



[Submit Abstract](#)

**ISV BOARD ELECTIONS  
2026-2027 TERM**



International  
Society for  
**VACCINES**

HELP SHAPE THE FUTURE OF VACCINES!

ISV

**BOARD  
ELECTIONS**

BOARD POSITIONS AVAILABLE

▶ PRESIDENT-ELECT

▶ TREASURER

▶ GENERAL SECRETARY

▶ BOARD OF DIRECTORS

▶ 7 SEATS FOR ORDINARY MEMBERS

▶ 3 SEATS FOR ISV FELLOWS

Thank you to those who submitted ISV Board Nominations for the 2026-2027 Term.

The Nomination Committee will review all submissions and present a slate of candidates for election by the ISV membership.

Voting will occur via email ballot, distributed one month prior to the ISV Annual General Meeting (AGM) and closing one week after the AGM.

In-person paper ballots will be available at the ISV AGM.

## ISV BOARD MEMBER INTRODUCTION

**Lenny Moise**

*SeromYx Systems / ISV Treasurer*



**What is your background/profession?**

Currently, I serve as Vice President of Research at SeromYx Systems, a CRO that specializes in profiling antigen-specific antibody Fc functions and translating complex immunological data into insights that inform vaccine development and therapeutic innovation. I lead a collaborative team of laboratory and computational scientists who conduct Systems Serology studies that combine high-throughput biophysical and functional assays and multivariate analytics to discern Fc-related antibody features associated with clinical outcomes.

Prior to joining to SeromYx, I served as Director of Vaccine Research at EpiVax, where my work centered on designing human and animal infectious disease vaccines that exploit T cell immunity employing immunoinformatic tools, and evaluating them in preclinical immunogenicity and efficacy studies. While at EpiVax, I served as research faculty at the University of Rhode Island at the Institute for Immunology and Informatics and at the University of Georgia at the Center for Vaccines and Immunology. I hold a PhD from Brown University, where I studied structure-function relationships of ion channel-neurotoxin interactions using biochemical, structural, and electrophysiological methods.

**What is your favorite/main research area/topic?**

Systems Immunology – sampling and integrating diverse immune responses to identify patterns and relationships among immune features for discovery of immune signatures associated with protection, pathology, or therapeutic response.

**What's your main scientific achievement/s?**

I have had the privilege of contributing to scientific advances through collaborative work in reverse vaccinology, characterization of human immune responses to infection and vaccination, host-pathogen T cell cross-reactivity, and protein design by epitope modification. While I value these accomplishments, I'm most proud of cultivating scientific curiosity, professional growth, and excellence in the next generation of scientists.

**Do you have any hidden talent/s?**

Homeschooling: Together with my wife, Professor Sigal Gottlieb (UMass Dartmouth), I homeschooled my two sons, who are now in doctoral programs in math.

**Annaliesa Anderson**

*Pfizer Inc. / ISV Board Member*



**What is your background/profession?**

I am a PhD/DSc h.c. and joined industry after completing two postdoctoral fellowships over 25 years ago.

**What is your favorite/main research area/topic?**

In the early stages of my career, I was deeply passionate about microorganisms and how they interacted with their environment by making molecules that could be used for medicines. However, most of my career has been dedicated to vaccine research and development. This field merges cutting-edge science with potentially significant public health impacts, striving to prevent diseases and save lives worldwide. It presents both challenges and rewards, and it has afforded me the opportunity to collaborate with thousands of remarkable colleagues and peers from around the globe.

**What's your main scientific achievement/s?**

I would say certainly anytime a vaccine or therapeutic that I've directly worked on gets licensed is absolutely a career highlight for me. These include a 13-valent pneumococcal conjugate vaccine (PCV); 20-valent PCV, meningococcal group B (MenB) vaccine; pentavalent meningococcal vaccine; mRNA-based COVID-19 vaccine; maternal and older adult respiratory syncytial virus vaccines; and the first licensed oral antiviral therapeutic against COVID-19. Approved vaccines have the potential to significantly improve people's lives, and that is ultimately what makes all the hard work worthwhile. Achieving these breakthroughs requires a deep understanding of how a pathogen causes disease so we can effectively combat it. This understanding comes from our internal researchers as well as collaborations with academic institutions. It is through this collaborative scientific environment that discoveries are made, driving the advancement of public health.

But beyond those accomplishments, I would say being given the opportunity to lead a large, global vaccine research and development organization is certainly a career highlight. We have such a talented and dynamic group of scientists, clinicians, engineers, and professional staff, and it truly is a privilege and an honor to be at the helm of our organization, especially with all the important work we have left to do ahead of us.

**Do you have any hidden talent/s?**

I enjoy gardening and, though clearly not a talent, have been trying to grow apple trees for many years. I have yet to have success due to pests and the climate, but I'm not giving up!

## **ISV COMMITTEE MEMBER INTRODUCTION**

**Ravi Degun**

*EY Parthenon Strategy*

*ISV Vaccine Industry Interaction Committee*



### **What is your background/profession?**

Ravi is a Partner at EY-Parthenon, and the Strategy Sector Lead for Health Science & Wellness. With over 20 years of experience, he is a specialist in commercial launch, portfolio strategy, R&D and market access. Ravi has supported biopharma, med-tech and healthcare clients globally across a range therapeutic areas and stratified conditions. He has worked in academia, government research and consulting (with Accenture, PA Consulting Group, Thomson Reuters and Guidehouse/Navigant).

Prior to joining EY, Ravi was a Partner in the Life Science Strategy Practice at Guidehouse, where he was the International Team Lead (London, Berlin, Zug, Shanghai, Beijing and India offices) and UK/International Managing Partner.

Ravi has a PhD. In Vaccine Development, from the GKT Medical School, King's College London, and a BSc. (Hons.) in Molecular Biology & Genetics. To compliment his scientific background, Ravi studied business strategy at Tanaka Business School, Imperial College (London), and has undertaken Executive programs at London Business School. He has lectured at the Mack Institute for Innovation Management at Wharton business school on how innovation in R&D translates to productivity and has published numerous scientific papers/posters.

### **What is your favorite/main research area/topic?**

Ravi has a scientific interest in infectious diseases (HIV, Covid, RSV, having supported the launch of the first RNA Covid vaccine), cell & gene therapy (oncology)

and rare conditions.

**What's your main scientific achievement/s?**

I've supported the development and commercial launch of some of the most innovative therapies over the past two decades, ranging from CarT therapies, RNA Vaccines, combination therapies and precision medicine.

**Do you have any hidden talent/s?**

As a new dad (22-month-old daughter) I have been putting my lab training to good use in measuring/mixing baby formula as well as following protocols on preparing baby/toddler meals.

**Branka Grubor**

*The University of Adelaide*

*ISV Outreach and Public Engagement Committee*



**What is your background/profession?**

I am an Associate Professor in Immunology and Vaccine Science at The University of Adelaide, (Adelaide, Australia) where I lead the Viral Immunology Group and co-direct the Adelaide RNA Innovation Hub. My background in virology and immunology, combined with prior experience in the biotech sector, has shaped my translational research program focused on advancing RNA and DNA based vaccines and immunotherapies for infectious diseases.

**What is your favorite/main research area/topic?**

My research centres on rational antigen design and next-generation vaccine platforms, with a focus on viral pathogens where vaccine solutions are urgently needed, including hepatitis C virus, Zika virus and pan-flavivirus vaccines. My team uses structure-guided and cohort-informed approaches to optimise antigen selection and design, and we are developing novel nanoparticle-based delivery systems to



enhance immune responses and scalability. I also have a strong interest and lead a research program in clinical immunology, particularly in understanding immune responses to vaccines and viral infections in vulnerable populations.

**What's your main scientific achievement/s?**

A key achievement has been the development of a novel Zika virus vaccine candidate that targets the conserved non-structural protein NS1, offering protective immunity while avoiding the risk of antibody-dependent enhancement (ADE) of infection commonly associated with flaviviruses. My team is also advancing a self-assembled nanoparticle-based platform for different viruses that presents optimised antigens using structure-guided engineering to support broad, effective immune responses. In the clinical setting, I lead research into immune dysregulation in long COVID, including biomarker discovery and therapeutic strategies, as well as immune profiling of immunosuppressed and critically ill patients with respiratory viral infections and sepsis. These multidisciplinary efforts have informed national health policy, including contributions to the Australian Government's Rapid Research Information Forum and direct advisory roles to the South Australian Chief Medical Officer during the COVID-19 pandemic.

**Do you have any hidden talent/s?**

As a kid, I dreamed of becoming a journalist and in a way, I've found a path back to that through my love of tennis. I'm a passionate tennis fan and have been fortunate to report from major international tournaments, including the Australian Open, for Sport Klub, a leading sports outlet in the Balkans region in Europe. It's a side of my life where I get to combine my passion for sport with storytelling, and media, including interviewing top tennis players.

**Linda Lua**

*The University of Queensland  
ISV Mentorship Committee*



**What is your background/profession?**

I am a Professor Emeritus at The University of Queensland, Australia, with a PhD in Biological Engineering and a lifelong passion for solving complex biotechnology challenges. Alongside my academic career, I am an Executive Coach and Consultant at The Growth Impact Pty Ltd, where I draw on my scientific expertise and leadership experience to support individuals and organizations in their growth journeys.

**What is your favorite/main research area/topic?**

Virus-like particle (VLP) technology has always fascinated me. Engineering the complex quaternary structure of a VLP to mimic a native virus is both intellectually rewarding and technically challenging. My research has focused on creating an integrated platform for customizing and manufacturing VLPs to target diseases such as rotavirus and avian influenza. In simple terms, this involves “dressing” core structural proteins with specific antigens to produce targeted immune responses. I've also contributed to the development of vaccine candidates using native virus-derived VLPs.

**What's your main scientific achievement/s?**

I enjoy working in cross-functional teams to foster innovation across both academia and industry. One of the most rewarding experiences in my career was founding and leading a contract research organisation that has supported hundreds of researchers in advancing translational science. I've also helped develop platform technologies for efficiently producing a wide range of antigens for disease surveillance. These antigens play a critical role in enabling timely public health responses to diseases like COVID-19, dengue, and malaria.

**Do you have any hidden talent/s?**

Baking themed cakes as a creative and therapeutic outlet, and people-watching to better understand human behavior.

## **ISV COMMITTEE UPDATE**

**Manon Cox**

*NextWaveBio*

*ISV Vaccine Industry Interaction and Fundraising Committee*



Aligned with our overarching mission to bring together scientists from across the globe at all stages of their careers to exchange knowledge and inspire solutions to diseases that can benefit from vaccine and immunotherapeutic interventions, our specific objective is to increase global awareness for our Society by strengthening partnerships and collaborations between academic and industry leaders.

The vaccine committee members have various backgrounds ranging from large, to small vaccine or biotech companies, consulting and academic organizations and are introduced in the Figure below. We meet monthly and exchange ideas on how to further engage our industry partners. Many of these ideas are generated through ongoing discussions with colleagues from the industry.



The first initiative of our committee was aimed at creating sustainable solutions required to support our programs and thus we focused setting up partnership packages for companies to ensure active industry participation. These sponsorship packages include various benefits such as memberships to our organization, attendance of our annual meetings, newsletter but most of all the opportunity to network and find those connections that may be mutually beneficial. Sponsors and partners are recognized at the ISV website and our events. In addition, we have an ongoing outreach to individuals including officers, board members, our fellows and others to encourage them to actively contribute to our Society. A wonderwall on ISV website now lists donations from individuals developed by Anna and Ted. [ISV Donors – The International Society for Vaccines](#)

Our second initiative around the **mini-symposia** stemmed from conversations with Markay Hopps (Pfizer). Markay mentioned that every organization has budget limitations and in large companies there are many great scientists who would love to attend international conferences within their area of research. However, they aren't able due to budget constraints. Our first symposium -held in January- on pneumococcal diseases featured speakers from the previous year pneumococcal society (ISPPD) including their President Cyntia Whitney. Similarly, the second one -held in April- focused on RSV and the third one on HIV. These symposia are recorded and can all be viewed on the ISV YouTube channel. Preparations for the fourth and last 2025 symposium on influenza are well underway and this symposium will be held on September 25.

The preliminary schedule for 2026 is listed below:

Topic	Preliminary Date
Human MetaPneumovirus	22 January 2026
AI use in vaccine Development	23 April 2026
Passive Antibody protection (i.e. mABs used as vaccines)	23 July 2026
Influenza or combination vaccines	24 September 2026

Our new 2026 initiative is to develop a virtual training course for industry professionals and academics and will be led by Xuefei Xhou. We are exploring the possibility for accreditation and hope to provide further updates soon.

This is just in a nutshell how we are contributing to increasing awareness and engagement with our stakeholders. If you are interested in joining our committee, have ideas for symposia or other things we would be happy to hear from you!

## VACCINE NEWS FLASH

**Xuefei Zhou**  
*XZ GMP Consulting, LLC*





## Hot Topics on Vaccines

### ***1. Moderna flu shot outperforms marketed vaccines in large late-stage trial***

- Moderna's seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed shot targeting three or four strains of the virus
- Moderna will begin discussing an approval submission with the Food and Drug Administration, aiming to launch what would be the first messenger RNA-based influenza vaccine in the U.S. as early as the 2026-2027 flu season.

### ***2. HIV pharma leaders are in Kigali, Rwanda for IAS 2025, presenting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval.***

- The HIV space saw a historic moment last month with the [approval](#) of Gilead's Yeztugo, a long-acting preventive injectable for HIV.
- The annual meeting of the International AIDS Society (IAS) is riding these tailwinds. The conference, currently being held in Kigali, Rwanda, is headlined by pharmas with some of the biggest developments in the field presenting the latest developments in their pipelines.

### ***3. The FDA issued a full nod to Moderna's COVID-19 shot this week for children aged 6 months to 11 years old, but the agency included a caveat that the vaccine should only be administered to kids at high risk for severe outcomes.***

### ***4. RFK Jr.-appointed panel recommends flu shots be free of contested preservative***

- Advisers to the Centers for Disease Control and Prevention recommended Thursday that influenza vaccines used in the coming flu season be free of the preservative thimerosal, addressing unproven fears the mercury-containing substance can lead to developmental disabilities.
- If confirmed by the CDC, the recommendation from the Advisory Committee on Immunization Practices, or ACIP, would affect about 5% of flu shots administered in the U.S., distributed in multidose vials that necessitate the use of a preservative to prevent bacterial or fungal contamination. Only three such vaccines are approved for U.S. use, two from CSL and one from Sanofi.

## 2024 CONGRESS AWARD RECIPIENTS: REFLECTIONS

**Elias Broeckhoven, KU Leuven, Belgium**

Awards for PhD Students and Early Career Researchers from Non-LMICs to Attend the ISV Congress (***Supported by ISV***)

**Awarded:** Joint 3<sup>rd</sup> Place - *Bright Sparks PhD Oral Presenter Award*

**Presentation Title:** *Efficient HBV Immunization Using a Self-Powered Microfluidic Chip for Reconstitution and Intradermal Delivery of CpG-adjuvanted HBs Vaccine*

In October 2024, I had the incredible opportunity to attend the ISV Meeting in Seoul, South Korea, thanks to the support of a Trainee Award. This event allowed me to expand my horizons beyond the lab benches that are typically my domain. Over the course of the 3-day conference, I attended numerous talks and workshops, gaining invaluable insights and perspectives from all presenters and moderators.

The conference also featured various social events, such as the poster sessions, which provided a fantastic platform to network and connect with like-minded, top-level individuals who share a passion for vaccine research.



It was refreshing to interact with these brilliant minds and explore potential collaborations with other member institutes in such a pleasant setting.

Additionally, the career development workshop and mentorship program offered us the amazing opportunity to learn from and interact with top-level members in the field. These sessions provided, and will continue to provide, valuable guidance on shaping our future paths and careers.

This award has given me the chance to participate in a prestigious gathering at an early stage in my academic and professional career. The connections and insights I gained will undoubtedly shape my future for the better. I am deeply grateful to ISV for providing students with such a unique and enriching opportunity.

**Imen Ayouni Ep Labidi, University of Cape Town, South Africa**

Awards for PhD Students and Early Career Researchers from LMICs to Attend the ISV Congress (***Supported by The Gates Foundation***)

**Awarded:** 2nd Place - *PhD Poster Presenter Award*

**Presentation Title:** *Intention to receive COVID-19 and Influenza vaccines during pregnancy: a prospective cross-sectional study among pregnant women attending antenatal care in Cape Town.*

I am pleased to submit this report regarding my attendance at the ISV 2024 conference held in Seoul, South Korea, from October 21st to 23rd, 2024 as an ISV Congress Award Recipient. As a PhD student, this event provided me

with an incredible opportunity to enhance my knowledge in vaccinology. I was able to learn from leading researchers and scholars, gaining valuable insights into the latest research and innovations in vaccine development.

The conference also allowed me to engage with peers and experts, fostering meaningful discussions that will shape my future research.



Presenting my work at ISV 2024 was an exceptional experience. I had the opportunity to present both an oral and a poster presentation, showcasing my research to an international audience. I am particularly honored to have received second place for the Best PhD Poster Presentation Award, which further validated the significance of my work.

ISV 2024 was a rewarding and enriching experience that contributed greatly to my academic and professional development. I am grateful for the opportunity and look forward to applying the knowledge and feedback I received to my future endeavors.

## ISV PAPERS OF THE MONTH

The ISV Outreach Committee Members review vaccine literature published in the last month and nominate 2-3 papers for consideration. Committee Members then vote on the nominated papers and the paper receiving the majority of votes is selected as the paper of the month.

### JUNE 2025 PAPER OF THE MONTH

#### **Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants**

*npj Vaccines* **10**, 110 (2025). <https://doi.org/10.1038/s41541-025-01166-1>

#### **Authors**

Gontu, A., Misra, S., Chothe, S.K. *et al.*

#### **Abstract**

SARS-CoV-2 continues to evolve and evade vaccine immunity necessitating vaccines that offer broad protection across variants. Conventional mRNA vaccines face cost and scalability challenges, prompting the exploration of alternative platforms like

trans-amplifying (TA) mRNA that offer advantages in safety, manufacturability, and antigen dose optimization. Using consensus sequence of immunodominant antigens is a promising antigen design strategy for broad cross-protection. Combining these two features, we designed and evaluated a TA mRNA vaccine encoding a consensus spike protein from SARS-CoV-2. Mice receiving the TA mRNA vaccine produced neutralizing antibody levels comparable to a conventional mRNA vaccine using 40 times less antigen mRNA. In hACE2 transgenic mice challenged with the Omicron BA.1 variant, the TA mRNA vaccine reduced lung viral titers by over 10-fold and induced broadly cross-neutralizing antibodies against multiple variants. These findings highlight the potential of TA mRNA vaccines with consensus antigen design, to improve efficacy and adaptability against SARS-CoV-2 variants.

## **JULY 2025 PAPER OF THE MONTH**

### **Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial**

*Nat Commun* **16**, 6118 (2025). <https://doi.org/10.1038/s41467-025-61153-x>

#### **Authors**

Ma, C., Du, J., Lan, L. et al.

#### **Abstract**

Identifying an immunologic marker as a correlate of protection (CoP) for RSV vaccination is important. In the pivotal phase 3 trial, the mRNA-1345 vaccine demonstrated efficacy against RSV in older adults (NCT05127434). Here, we evaluate neutralizing antibodies (nAb) against RSV-A and -B, and IgG binding antibodies (bAb) to RSV fusion antigens as correlates of risk (CoR) and CoP against the pivotal trial's efficacy endpoints of RSV lower respiratory tract disease with  $\geq 2$  or  $\geq 3$  signs/symptoms (RSV-LRTD-2+ and -3+) and acute respiratory disease (RSV-ARD). Day 29 RSV nAb and pre-fusion (preF) IgG demonstrate consistent inverse correlates with RSV endpoint occurrence. Day 29 point estimates (95% CIs) of the hazard ratio of each endpoint (RSV-LRTD-2+, RSV-LRTD-3+, RSV-ARD) per 10-fold increase in RSV-A nAb are 0.44 (0.30-0.65), 0.41 (0.20-0.84), and 0.45 (0.28-0.71), respectively, similar to RSV-B nAb and preF IgG. These results demonstrate Day 29 RSV nAb and preF IgG are CoRs and support their role as CoPs against RSV endpoints.



## 2025 ISV August Webinar

Wednesday, 27 August 2025



**Andrew Ward**  
*Scripps Research, USA*

**US & Europe**  
27 August

08:00 (PDT)  
11:00 (EDT)  
16:00 (BST)  
17:00 (CEST)

**South America**  
27 August

12:00 noon (Argentina)  
09:00 (Mexico)

**Africa**  
27 August

16:00 (West Africa)  
17:00 (South Africa)  
18:00 (East Africa)

**Asia**  
27 August

20:30 (IST)  
23:00 (CST)  
00:00 midnight (KST)

**Australia**  
27 August

23:00 (AWST)  
01:00 (AEST) - 28 August

Join Here:  
<https://zoom.us/j/99951071640>

## Next Generation Vaccinologists Webinar Series 07 August 2025

*Mapping B Cell Precursors in HIV: A Southern African  
Perspective on Germline-Targeting Vaccine Strategies*

**Dr. Judie Magura**  
*Africa Health Research Institute (AHRI), South Africa*



*Being resourceful in an under-resourced research  
landscape: leveraging optimism and collaboration*  
*Focus: foot and mouth disease virus (FMDV)*

**Dr. Keba Lebani**  
*Botswana International University of Science and Technology,  
Botswana*

**Moderator: Dr. Sandra Depelsenaiere,**  
Vaxxas Pty Ltd

**US & Europe**

01:00 (PDT)  
04:00 (EDT)  
09:00 (BST)  
10:00 (CEST)

**South America**

02:00 (Mexico)  
05:00 (Argentina)

**Africa**

09:00 (WAT)  
10:00 (SAST)  
11:00 (East Africa)

**Asia**

13:30 (IST)  
16:00 (CST)  
17:00 (KST)

**Australia**

16:00 (AWST)  
18:00 (AEST)

**Thursday, August 07<sup>th</sup>**

Join Webinar here:  
<https://zoom.us/j/99066618294>

## ISV WELCOMES ITS NEWEST MEMBERS

Simin Li  
Veronika Chromikova  
Steve Lamola  
William Golde  
Davinder Gill  
Kanitha Patarakul  
Elena Atochina-Vasserman  
Kwadwo Koram

Stephen Chiweshe  
Alyson Kelvin  
Samson Nzou  
Nicholas Cerda  
Swayam Pragyan Parida  
Adriana Tomic  
Luis Barreto





## Membership Benefits



Save up to US\$100 on  
ISV Annual Congress



Mentorship & Global  
Networking opportunities



Exclusive Newsletter with  
the latest vaccine news



Career Growth  
Opportunities



Journal Access &  
Discounts



Eligibility to join ISV  
Committees & run for  
Officer & Board positions



**Connect, Collaborate, Innovate!**



**Stay Engaged with the ISV through its Social Media  
Channels:**

[ISV on YouTube](#)

[ISV on LinkedIn](#)

[ISV on Facebook](#)

ISV on Instagram

ISV on X

ISV on Bluesky

International  
Society for  
**VACCINES**

# SAVE THE DATE!

ISV-ONLINE.ORG

# 2026 ISV ANNUAL CONGRESS

12 - 14 OCTOBER, 2026 | ANTWERP | BELGIUM

PARTNER





GOLD



SILVER



OTHER



If you no longer wish to receive email from us, please click [here](#)